Publications for Mehmet F. Ozkaynak

NYMC School of Medicine
  • Mehta, B., Militano, O., Ozkaynak, M. F., van de Ven, C., Nickerson, B. A., Hamby, C.,. . . Cairo, M. S. (2016). Mycophenolate mofetil (MMF) administered every eight hours with tacrolimus is efficacious in acute graft versus host disease (aGVHD) prophylaxis in childhood, adolescent and young adult (CAYA) allogeneic hematopoietic progenitor transplant (ALLOHPT) recip. Pediatric Blood & Cancer, 63(Suppl S1), S97.

  • Chen, N., Radhakrishnan, K., Krajewski, J., Ricci, A., Geyer, M., Harrison, L., Ozkaynak, M. F., . . . Cairo, M. S. (2014). Low day 100 transplant-related mortality and relapse rate following clofarabine in combination with cytarabine, total body irradiation and allogenic stem cell transplantaiton in children, adolescents and young adults with poor-risk acute leukemia. Biology of Blood and Marrow Transplantation, 20(2 Suppl), S79-S80.

  • Ozkaynak, M. F. (2014). Pediatric neuroblastoma: Combined treatment with monoclonal antibody and cytokines preceded by hematopoietic stem cell transplantation. In M. A. Hayat (Ed.), Stem cells and cancer stem cells (pp. 209-220). Netherlands: Springer Science+Business Media.

  • Ozkaynak, M. F., Gilman, A. L., Yu, A. L., London, W. B., Sondel, P. M., Smith, M. A., . . . Park, J. R. (2014). A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF / IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. Journal of Clinical Oncology, 32(15 Suppl), 10044.

  • Yu, A., Gilman, A. L., Ozkaynak, M. F., Sondel, P. M., London, W. B., Cretella, S., . . . Park, J. R. (2014). Update of outcome for high-risk neuroblastoma treated on a randomized trial of chimeric anti-GD2 antibody (ch14.18) + GM-CSF / IL2 immunotherapy in 1st response : A Children's Oncolgy Group study.. Advances in Neuroblastoma Research,  108.